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Available online 1 October 2014In humans, the intestinal epithelium is a single layer of cells
that constitutes one of the most important barriers between
internal and external environments. The so-called ‘intesti-
nal barrier’ (IB) is a dynamic structure composed of different
types of cellular junctions that can be regulated by physio-
logical and pathological stimuli, and act as a selective barrier
to antigens and pathogens. Physiological mechanisms that
regulate IB function are important for nutrient absorption
and antigen permeation, with potential roles in the regula-
tion of tolerance to non-self antigens.1 However, pathological
stimuli such as pathogens, cytokines and immune cells are
also capable of affecting IB function as demonstrated in stud-
ies about tumor necrosis factor alpha (TNF-)-mediated IB
disruption.2 Accordingly, a model known as ‘leaky gut syn-
drome’ has emerged based on the concept that TNF-mediated
cycles of increased IB permeability may lead to translocation
of macromolecules from the lumen into the lamina propria,
and to amplification of mucosal immune activation. In the
absence of appropriate regulatory signals, this vicious cycle
may result in local or systemic immune-mediated diseases,
such as Celiac disease, Crohn’s disease, food allergies, and
even type-1 diabetes mellitus.3
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reserved.Disrupted IB function has been described in patients with
hematological malignancies, in whom it can occur as a
consequence of cytotoxic therapy-induced epithelial damage
or leukemic infiltration.4,5 The most straightforward conse-
quences of IB disruption for these patients are increased
antigen permeation, which could facilitate pathogen translo-
cation, bacteremia, and nutrient malabsorption.6 Interest-
ingly, an additional consequence of IB disruption in patients
with hematological malignancies is a higher risk of acute
graft-versus-host disease (aGVHD) in patients submitted to
allogeneic hematopoietic stem cell transplantation (HSCT).
In this context, translocation of luminal contents and acti-
vation of the underlying antigen presenting cells would
enhance activation and proliferation of alloreactive donor
cells. This could result in greater inflammatory cytokine
production, sustained damage to endothelial and epithe-
lial barriers, and donor T-cell infiltration. Together, these
events have the potential of facilitating the development
of aGVHD, as suggested by the observation of a higherversidade Estadual de Campinas (UNICAMP), Rua Carlos Chagas,
risk of aGVHD in patients with increased IB permeability.7
Of note, it has been proposed that barrier-protecting
agents could be beneficial for conditions associated with
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his pathogenic model, although no clinical data are yet
vailable.3
In the current edition of the Revista Brasileira de Hema-
ologia e Hemoterapia, Leite et al. report the measurement
f IB permeability in patients with leukemia.8 Although no
tatistically significant results could be demonstrated, and
he categorization of ‘leukemias’ used by the authors, which
ncludes acute myeloid leukemia (AML), chronic myeloid
eukemia (CML) and chronic lymphocytic leukemia (CLL) as
 single group, is of little biological significance, the report
as the merit of reintroducing the subject of IB disruption
o the agenda of malignant hematology. Using a classical
easurement tool, based on the differential absorption of
actulose and mannitol, the authors demonstrate a clear
rend toward increased IB permeability in patients with acute
eukemia, before chemotherapy. Previous studies found sim-
lar results,5,9 indicating that IB disruption is indeed present
n some of these patients, even before chemotherapy. Contro-
ersial results were obtained in patients before conditioning
rior to HSCT, but IB disruption could always be detected after
hemotherapy.7,9
Considering the critical role of IB function in immune
egulation, as well as recent insights into the cellular and
olecular mechanisms that regulate barrier function in phys-
ological and pathological conditions, there is much more  than
gut feeling’ to support the relevance of the question addressed
y Leite et al. to the field of malignant hematology.8onflicts  of  interest
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